A study in cognitively unimpaired Amyloid beta positive individuals has shown that serum levels of GFAP, can predict development of Tau pathology, which has the likelihood of progressing into Alzheimer’s disease with cognitive impairment (Bellaver et al., 2023). The gene discussed is GFAP; the disease is Alzheimer disease.